Review
Gastroenterology & Hepatology
Francesco Crafa, Serafino Vanella, Onofrio A. Catalano, Kelsey L. Pomykala, Mario Baiamonte
Summary: Current histopathological staging procedures in colorectal cancer may lead to understaging in high-risk patients. The one-step nucleic acid amplification assay is a rapid molecular diagnostic tool with high accuracy and negative predictive value, which can help improve staging accuracy.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Oncology
Maria Dolores Diestro, Alberto Berjon, Ignacio Zapardiel, Laura Yebenes, Irune Ruiz, Arantza Lekuona, Marta Rezola, Ibon Jaunarena, Jaime Siegrist, Margarita Sanchez-Pastor, Maria Cuadra, Amaia Sagasta, Isabel Guerra, Luis Lete, Fernando Roldan, Carlo B. Marta, Maria Boillos, Maria Cardiel, Carlos Lopez-de la Manzanara, Fernanda Relea, Pluvio Coronado, Alejandro Pascual, Maria Roman, Gloria Peiro, Luis Matute, Beatriz Montero, Juan Muruzabal, Rosa Guarch, Cristina Zorrero, Ana Calatrava, Laia Ribot, Irmgard Costa, Alicia Hernandez, David Hardisson
Summary: One-step nucleic acid amplification (OSNA) is an automated molecular diagnostic assay used to detect metastases by analyzing the levels of cytokeratin 19 mRNA in whole lymph nodes. It has higher sensitivity, specificity, and diagnostic accuracy in detecting sentinel lymph node metastasis in patients with early-stage endometrial cancer compared to standard pathological ultrastaging, potentially aiding in the identification of patients requiring adjuvant treatment.
Review
Endocrinology & Metabolism
Xiaofei Wang, Xun Zheng, Jingqiang Zhu, Zhihui Li, Tao Wei
Summary: The results of this meta-analysis show that OSNA assay has high accuracy for intraoperative diagnosis of lymph node metastasis in PTC, making it an effective molecular diagnostic method.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Shinichi Togami, Akihide Tanimoto, Shintaro Yanazume, Hideki Tokunaga, Tomoyuki Nagai, Mika Watanabe, Hideaki Yahata, Kazuo Asanoma, Hidetaka Yamamoto, Tomohito Tanaka, Masahide Ohmichi, Takashi Yamada, Yukiharu Todo, Ryutaro Yamada, Hidenori Kato, Wataru Yamagami, Kenta Masuda, Miho Kawaida, Hitoshi Niikura, Takuya Moriya, Hiroaki Kobayashi
Summary: This multicenter study aimed to evaluate the accuracy of the OSNA assay in diagnosing LNM in cervical and endometrial cancer patients. The OSNA assay showed high concordance, sensitivity, and specificity compared to histopathological examination. Therefore, the OSNA assay may be a useful tool for the rapid intraoperative diagnosis of LN metastasis in patients with cervical and endometrial cancers.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Bruno Maerkl, Bianca Grosser, Kerstin Bauer, Dmytro Vlasenko, Gerhard Schenkirsch, Andreas Probst, Bernadette Kriening
Summary: This study compared the effectiveness of OSNA in combination with ex vivo SLN mapping with conventional histology in gastric cancer cases. OSNA showed high sensitivity, specificity, and accuracy rates, and potential to increase metastases detection sensitivity.
Article
Oncology
Shinichi Togami, Takashi Ushiwaka, Ikumi Kitazono, Shintaro Yanazume, Masaki Kamio, Akihide Tanimoto, Hiroaki Kobayashi
Summary: This study evaluated the accuracy of the one-step nucleic acid amplification (OSNA) assay in the diagnosis of lymph node metastasis in uterine cancer. The results showed high concordance rate, sensitivity, and specificity of the OSNA assay, indicating that it could enhance the accuracy of conventional pathological examination for the detection of lymph node metastasis by reducing false negative rate.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2022)
Article
Cell Biology
Maria Teresa Hermida-Romero, Lara S. Estevez-Perez, Begona O. Alen, Florencia Picchi, Ricardo Fernandez-Prado, Mercedes De La Torre-Bravos, Angel Concha
Summary: The OSNA method allows for quantitative evaluation of tumor burden in lymph nodes of lung cancer patients and can be used as a predictive marker for recurrence and survival. This technique facilitates appropriate follow-up after surgery, leading to improved survival rates in lung cancer patients.
Article
Chemistry, Analytical
Yong Chen, Xiaoling Xu, Jiachun Wang, Yibin Zhang, Wentao Zeng, Yizhen Liu, Xueji Zhang
Summary: A photoactivated CRISPR/Cas12a strategy was proposed in this study to achieve high-sensitivity nucleic acid detection in one pot, avoiding amplicon contamination and lowering the threshold for molecular diagnostics in POC.
ANALYTICAL CHEMISTRY
(2022)
Article
Surgery
Benjamin Weixler, Sofia Teixeira da Cunha, Rene Warschkow, Nicolas Demartines, Ulrich Guller, Andreas Zettl, Alexander Vahrmeijer, Cornelis J. H. van de Velde, Carsten T. Viehl, Markus Zuber
Summary: This study evaluated the prognostic value of one-step nucleic acid amplification (OSNA) in colon cancer, finding that OSNA did not add relevant prognostic value compared to conventional haematoxylin and eosin (H&E) staining. Lower thresholds for OSNA should be assessed in future studies.
WORLD JOURNAL OF SURGERY
(2021)
Article
Oncology
Cas de Jongh, Lianne Triemstra, Arjen van Der Veen, Lodewijk A. A. Brosens, Misha D. P. Luyer, Jan H. M. B. Stoot, Jelle P. Ruurda, Richard van Hillegersberg
Summary: This study analyzed the patterns of lymph node metastases in gastric cancer patients and found that different tumor locations contribute to different metastatic patterns. However, regardless of tumor location, tumor stage, histological subtype, or neoadjuvant chemotherapy, all lymph node stations may contain metastases.
Article
Oncology
Eleonora La Fera, Nicolo Bizzarri, Alessandro Petrecca, Giorgia Monterossi, Giorgia Dinoi, Gian Franco Zannoni, Stefano Restaino, Emilia Palmieri, Laura Mariuzzi, Inge Peters, Giovanni Scambia, Francesco Fanfani
Summary: The OSNA method showed high specificity and accuracy in detecting sentinel lymph node metastases in women with apparent early-stage endometrial cancer, and it eliminates sampling bias by analyzing the entire lymph node.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Gastroenterology & Hepatology
Yuma Wada, Mitsuo Shimada, Tatsuro Murano, Hiroyuki Takamaru, Yuji Morine, Tetsuya Ikemoto, Yu Saito, Francesc Balaguer, Luis Bujanda, Maria Pellise, Ken Kato, Yutaka Saito, Hiroaki Ikematsu, Ajay Goel
Summary: The study demonstrates that a blood-based liquid biopsy assay can accurately detect lymph node metastasis in high-risk T1 CRC patients, with the risk-stratification model proving to be more accurate than the transcriptomic panel, potentially avoiding unnecessary surgery for high-risk patients.
Article
Chemistry, Analytical
Kai Sun, Xueqi Wang, Yuxin Qu, Han Wang, Jing Cheng
Summary: The development of more accurate and adaptive molecular diagnosis technologies has been fostered by the emergence of the global pandemic and the discovery of nucleic acid biomarkers in cancer diagnosis. Current nucleic acid testing methods either lack sensitivity or require tedious amplification operations, which cannot meet the demand for point-of-care diagnosis. A fluorescence one-step-bDNA-based lateral flow assay (FOB-LFA) method for amplification-free nucleic acid testing is presented here, which demonstrated high sensitivity and specificity for SARS-CoV-2 detection, as well as potential for clinical examination. FOB-LFA shows outstanding performance in terms of sensitivity, specificity, cost, portability, and risk reduction, meeting the needs of point-of-care testing for various infectious and genetic diseases.
ANALYTICAL CHEMISTRY
(2023)
Article
Oncology
Jun Okuno, Tomohiro Miyake, Yoshiaki Sota, Tomonori Tanei, Naofumi Kagara, Yasuto Naoi, Masafumi Shimoda, Kenzo Shimazu, Seung Jin Kim, Shinzaburo Noguchi
Summary: The study aimed to identify microRNAs associated with sentinel lymph node metastasis (SLNM) in ER-positive and HER2-negative (ER+/HER2-) breast cancer and develop a prediction model for SLNM.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Svenja Engels, Lutz Brautmeier, Lena Reinhardt, Clara Wasylow, Friederike Hasselmann, Rolf P. Henke, Friedhelm Wawroschek, Alexander Winter
Summary: Prostate cancer is a common cancer among men, and the presence of lymph node metastases is a strong prognostic factor. One-step nucleic acid amplification (OSNA) can accurately detect metastases in sentinel lymph nodes with high sensitivity and specificity, showing good concordance with histopathological findings.
Article
Oncology
Masato Takahashi, Shoichiro Ohtani, Shigenori E. Nagai, Seiki Takashima, Miki Yamaguchi, Michiko Tsuneizumi, Yoshifumi Komoike, Tomofumi Osako, Yoshinori Ito, Masahiko Ikeda, Kazushige Ishida, Takahiro Nakayama, Tsutomu Takashima, Takashi Asakawa, Sho Matsumoto, Daisuke Shimizu, Norikazu Masuda
Summary: The COMACHI study confirmed the efficacy and safety of pertuzumab plus trastuzumab and docetaxel in Japanese patients with recurrent or metastatic HER2-positive breast cancer, showing similar results to the overall population of the CLEOPATRA study. This combination therapy can be considered as standard of care for Japanese patients with inoperable or recurrent HER2-positive breast cancer.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Medicine, General & Internal
Takayuki Ueno, Shigehisa Kitano, Norikazu Masuda, Daiki Ikarashi, Makiko Yamashita, Tomohiro Chiba, Takayuki Kadoya, Hiroko Bando, Takashi Yamanaka, Shoichiro Ohtani, Shigenori Nagai, Takahiro Nakayama, Masato Takahashi, Shigehira Saji, Kenjiro Aogi, Ravi Velaga, Kosuke Kawaguchi, Satoshi Morita, Hironori Haga, Shinji Ohno, Masakazu Toi
Summary: This study found that the density of CD4+ T cells in both the tumor and stromal regions is an independent predictor of pathological complete response (pCR) in patients with triple-negative breast cancer (TNBC). This predictive value is particularly strong in patients receiving platinum-containing chemotherapy.
Article
Oncology
Massimo Cristofanilli, Hope S. Rugo, Seock-Ah Im, Dennis J. Slamon, Nadia Harbeck, Igor Bondarenko, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Hiroji Iwata, Ben O'Leary, Fabrice Andre, Sibylle Loibl, Eustratios Bananis, Yuan Liu, Xin Huang, Sindy Kim, Maria Jose Lechuga Frean, Nicholas C. Turner
Summary: This study conducted a long-term analysis of overall survival (OS) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. The results showed that treatment with palbociclib plus fulvestrant significantly improved survival compared to placebo plus fulvestrant, particularly in patients with endocrine-sensitive disease, no prior chemotherapy for advanced breast cancer, and low circulating tumor fraction.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Norikazu Masuda, Makiko Ono, Toru Mukohara, Hiroyuki Yasojima, Tatsunori Shimoi, Kokoro Kobayashi, Kenichi Harano, Makiko Mizutani, Maki Tanioka, Shunji Takahashi, Takahiro Kogawa, Takuya Suzuki, Shiori Okumura, Takao Takase, Reiko Nagai, Taro Semba, Zi-Ming Zhao, Min Ren, Kan Yonemori
Summary: This study evaluated the safety and efficacy of a liposomal formulation of eribulin, E7389-LF, in breast cancer patients. The results showed that E7389-LF had favorable antitumor activity, particularly in hormone receptor-positive breast cancer patients. Prophylactic pegfilgrastim may be considered for reducing the risk of neutropenia and febrile neutropenia.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Norikazu Masuda, Yucherng Chen, Tsutomu Kawaguchi, Koji Dozono, Masakazu Toi
Summary: The purpose of this study was to examine the safety of abemaciclib in Japanese patients with advanced breast cancer. The analysis of data from two phase 3 studies showed that abemaciclib-treated Japanese patients had a higher incidence of diarrhea, neutropenia, and liver function abnormalities compared to the overall safety population. However, these adverse events were manageable with appropriate interventions.
CANCER MANAGEMENT AND RESEARCH
(2022)
Article
Oncology
Yutaka Yamamoto, Hiroji Iwata, Naruto Taira, Norikazu Masuda, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Hiroshi Tada, Fumikata Hara, Tomomi Fujisawa, Naoki Niikura, Shigehira Saji, Satoshi Morita, Masakazu Toi, Shinji Ohno
Summary: This study aimed to examine the efficacy of pertuzumab retreatment for HER2-positive locally advanced or metastatic breast cancer. The results showed that adding pertuzumab significantly improved progression-free survival in all patients and showed a trend towards better overall survival and duration of response.
Article
Oncology
Haruru Kotani, Norikazu Masuda, Toshinari Yamashita, Yoichi Naito, Tetsuhiko Taira, Kenichi Inoue, Masato Takahashi, Kan Yonemori, Shigeyuki Toyoizumi, Yuko Mori, Takashi Nagasawa, Natsuki Hori, Hiroji Iwata
Summary: This study evaluated the efficacy and safety of talazoparib in Japanese patients with gBRCA1/2-mutated advanced breast cancer. The results showed that talazoparib monotherapy resulted in clinically meaningful treatment response in patients with gBRCA mutations.
Article
Nanoscience & Nanotechnology
Yoshimasa Kosaka, Toshiaki Saeki, Toshimi Takano, Tomoyuki Aruga, Toshinari Yamashita, Norikazu Masuda, Yukio Koibuchi, Akihiko Osaki, Junichiro Watanabe, Ryu Suzuki
Summary: This study compared the efficacy and safety of NK105 and paclitaxel in the treatment of advanced recurrent breast cancer at equivalent dose levels. The results showed similar efficacy between the two groups, but a delayed onset of peripheral sensory neuropathy in the NK105 group.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2022)
Article
Oncology
Masaya Hattori, Norikazu Masuda, Toshimi Takano, Koichiro Tsugawa, Kenichi Inoue, Koji Matsumoto, Takashi Ishikawa, Mitsuya Itoh, Hiroyuki Yasojima, Yuko Tanabe, Keiko Yamamoto, Masato Suzuki, Wilbur Pan, Javier Cortes, Hiroji Iwata
Summary: In the KEYNOTE-355 trial, pembrolizumab plus chemotherapy showed improved progression-free survival (PFS) and overall survival (OS) compared to placebo plus chemotherapy in previously untreated patients with locally recurrent inoperable or metastatic triple-negative breast cancer. The study included Japanese patients, and the results were consistent with the global population. The combination of pembrolizumab and chemotherapy demonstrated manageable toxicity and supported its use in this setting.
Article
Oncology
Toshimi Takano, Mitsuya Ito, Takayuki Kadoya, Tomofumi Osako, Tomoyuki Aruga, Norikazu Masuda, Toshiko Miyaki, Naoki Niikura, Daisuke Shimizu, Yuichi Yokoyama, Manabu Watanabe, Masato Tomomitsu, Kenjiro Aogi
Summary: This study investigated the efficacy and safety of MD-110 in early-stage breast cancer patients receiving neoadjuvant or adjuvant myelosuppressive chemotherapy. The results showed that MD-110 was effective in reducing chemotherapy-induced neutropenia without additional safety concerns.
Article
Oncology
Misato Masuyama, Norikazu Masuda, Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno
Summary: The role of endocrine therapy in postmenopausal patients with ER-positive HER2-positive AMBC is unclear. The Safari study analyzed data from 94 patients and found that F500 therapy as first- or second-line treatment resulted in longer TTF. Furthermore, patients with TTC ≥ 3 years had prolonged OS, suggesting that this value could be used as a cut-off for predicting clinical outcomes.
Meeting Abstract
Oncology
Sara Hurvitz, Linda Vahdat, Nadia Harbeck, Antonio C. Wolff, Sara M. Tolaney, Sherene Loi, Norikazu Masuda, Joyce O'Shaughnessy, Cassie Dong, Luke Walker, Evelyn Rustia, Virginia F. Borges
Meeting Abstract
Oncology
Tsuguo Iwatani, Fumikata Hara, Tadahiko Shien, Masato Takahashi, Norikazu Masuda, Hiroyuki Yasojima, Yasuaki Sagara, Tomonori Mizutani, Keita Sasaki, Kenichi Nakamura, Haruhiko Fukuda, Takaru Shiroiwa, Hiroji Iwata
Meeting Abstract
Oncology
Masahiro Kashiwaba, Takahiro Nakayama, Takafumi Sangai, Takashi Morimoto, Hiroyuki Yasojima, Yutaka Yamamoto, Shinji Ohno, Norikazu Masuda
Meeting Abstract
Oncology
Ian Krop, Kan Yonemori, Shunji Takahashi, Kenichi Inoue, Takahiro Nakayama, Hiroji Iwata, Tatsuya Toyama, Yutaka Yamamoto, Masato Takahashi, Akihiko Osaki, Shigehira Saji, Yasuaki Sagara, Joyce O'Shaughnessy, Tiffany Traina, Shoichi Ohwada, Zhenhao Qi, Yang Qiu, Hiroshi Onuma, Om Sharma, Sabeen Mekan, Norikazu Masuda